Chronic kidney disease-associated pruritus (CKD-aP) is a chronic itching condition that is particularly common in patients on hemodialysis. It is a serious and common condition that is generally under-recognized and under-reported.
CKD-aP can significantly reduce patients’ quality of life (QoL) through the urge to scratch, impaired sleep, and depression, and can lead to worsening medical outcomes in severely affected patients.
The pathogenesis of CKD-aP is multifactorial; while formally attributed primarily to the accumulation of uremic toxins, new research indicates a significant role for kappa opioid receptor (KOR) dysregulation.
Sukul N, et al. Kidney Med 2020;3(1):42–53.
Chronic kidney disease (CKD)-associated pruritus, generalized itching related to CKD, affects many aspects of hemodialysis patients’ lives. However, information regarding the relationship between pruritus and several key outcomes in hemodialysis patients remains limited.
View this infographic to learn more about self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis.
Ramakrishnan K, et al. Int J Nephrol Renovasc Dis 2014;7:1–12.
One of the most common conditions affecting end-stage renal disease (ESRD) patients undergoing hemodialysis (HD) is pruritus. Studies report that itchy and dry skin, symptoms of pruritus, affect 40%–90% of ESRD patients. Yet, in clinical practice the condition is often underdiagnosed resulting in inadequate management and an underappreciated impact on patient outcomes.
View this infographic to learn more about clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms.
Rayner HC, et al. Clin J Am Soc Nephrol 2017;12:2000–7.
Uremic pruritus in patients on hemodialysis is associated with depression, lower quality of life, and mortality. The prevalence of pruritus in people on hemodialysis is decreasing but remains underestimated. Large numbers of patients on hemodialysis with severe pruritus do not receive treatment. There is wide variation in the use of unlicensed medications for the treatment of pruritus.
View this infographic to learn more about the prevalence, awareness, and treatment of pruritus.
Verduzco H, et al. Kidney Int Rep. 2020;5(9):1387–1402.
There are no universally accepted methods to measure CKD-aP, and this has led to a wide range of prevalence estimates. Currently used scales can be divided into those that measure severity, multidimensional scales that measure several itch characteristics, and scales that measure the impact of itching on quality of life (QoL).
View this infographic to learn more about the prevalence of CKD-aP.
Chronic kidney disease–associated pruritus (CKD-aP) is a common, troubling and in some cases debilitating problem for patients with CKD and end-stage renal disease. Despite a prevalence rate of approximately 20% in CKD and 40% in end-stage renal disease, and a clear association with poorer psychosocial and medical outcomes, this condition is often under-reported by patients and overlooked by healthcare providers.
View this infographic to learn more about adverse medical and psychosocial outcomes related to CKD-aP.
This is me, continue